Alimera Sciences is a pharmaceutical company that is engaged in the commercialization and development of prescription ophthalmic pharmaceuticals. Co. focuses on diseases affecting the back of the eye, or retina. Co.'s commercial product is ILUVIEN®, an intravitreal implant that treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye, for up to 36 months. ILUVIEN was initially developed to treat diabetic macular edema, a disease of the retina that affects individuals with diabetes and can lead to vision loss and blindness. Co. commercially markets ILUVIEN in the U.S., Germany, the U.K., Portugal, and Ireland. The ALIM stock yearly return is shown above.
The yearly return on the ALIM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALIM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|